1. Anticancer Ruthenium Complexes with HDAC Isoform Selectivity
- Author
-
Jasmine M. Cross, Tim R. Blower, Alexander D. H. Kingdon, Robert Pal, David M. Picton, and James W. Walton
- Subjects
histone deacetylase inhibitors ,ruthenium in medicine ,selective enzyme inhibition ,Organic chemistry ,QD241-441 - Abstract
The histone deacetylase (HDAC) enzymes have emerged as an important class of molecular targets in cancer therapy, with five inhibitors in clinical use. Recently, it has been shown that a lack of selectivity between the 11 Zn-dependent HDAC isoforms may lead to unwanted side-effects. In this paper, we show that piano stool Ru complexes can act as HDAC inhibitors, and variation in the capping arene leads to differences in HDAC isoform selectivity.
- Published
- 2020
- Full Text
- View/download PDF